Literature DB >> 26686090

FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.

V Fleskens1, M Mokry2, A M van der Leun1, S Huppelschoten1, C E G M Pals1, J Peeters1, S Coenen1, B A Cardoso3, J T Barata3, J van Loosdregt1,2, P J Coffer1,2.   

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex. Transcriptional activity of the TAL1-complex is thought to have a pivotal role in the transformation of thymocytes and is associated with a differentiation block and self-renewal. The transcription factor Forkhead Box P3 (FOXP3) was recently described to be expressed in a variety of malignancies including T-ALL. Here we show that increased FOXP3 levels negatively correlate with expression of genes regulated by the oncogenic TAL1-complex in human T-ALL patient samples as well as a T-ALL cell line ectopically expressing FOXP3. In these cells, FOXP3 expression results in altered regulation of cell cycle progression and reduced cell viability. Finally, we demonstrate that FOXP3 binds LMO2 in vitro, resulting in decreased interaction between LMO2 and TAL1, providing a molecular mechanism for FOXP3-mediated transcriptional modulation in T-ALL. Collectively, our findings provide initial evidence for a novel role of FOXP3 as a tumor suppressor in T-ALL through modulation of TAL1 transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26686090     DOI: 10.1038/onc.2015.481

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  58 in total

1.  Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.

Authors:  Teresa Palomero; Duncan T Odom; Jennifer O'Neil; Adolfo A Ferrando; Adam Margolin; Donna S Neuberg; Stuart S Winter; Richard S Larson; Wei Li; X Shirley Liu; Richard A Young; A Thomas Look
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice.

Authors:  G L Condorelli; F Facchiano; M Valtieri; E Proietti; L Vitelli; V Lulli; K Huebner; C Peschle; C M Croce
Journal:  Cancer Res       Date:  1996-11-15       Impact factor: 12.701

3.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

4.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

Authors:  Sebastian Hinz; Laia Pagerols-Raluy; Hans-Heinrich Oberg; Ole Ammerpohl; Sandra Grüssel; Bence Sipos; Robert Grützmann; Christian Pilarsky; Hendrik Ungefroren; Hans-Detlev Saeger; Günter Klöppel; Dieter Kabelitz; Holger Kalthoff
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

5.  FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.

Authors:  Tao Zuo; Runhua Liu; Huiming Zhang; Xing Chang; Yan Liu; Lizhong Wang; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells.

Authors:  Guo-Yun Chen; Chong Chen; Lizhong Wang; Xing Chang; Pan Zheng; Yang Liu
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

7.  Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells.

Authors:  Jeremy B Samon; Ameya Champhekar; Lisa M Minter; Janice C Telfer; Lucio Miele; Abdul Fauq; Pritam Das; Todd E Golde; Barbara A Osborne
Journal:  Blood       Date:  2008-06-11       Impact factor: 22.113

8.  TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Authors:  Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

9.  Transcription factor Foxp3 and its protein partners form a complex regulatory network.

Authors:  Dipayan Rudra; Paul deRoos; Ashutosh Chaudhry; Rachel E Niec; Aaron Arvey; Robert M Samstein; Christina Leslie; Scott A Shaffer; David R Goodlett; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2012-08-26       Impact factor: 25.606

10.  Notch1 signaling is involved in regulating Foxp3 expression in T-ALL.

Authors:  Xiaodan Luo; Huo Tan; Yueqiao Zhou; Tiantian Xiao; Chunyan Wang; Yangqiu Li
Journal:  Cancer Cell Int       Date:  2013-04-11       Impact factor: 5.722

View more
  5 in total

Review 1.  Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.

Authors:  N C Correia; M-L Arcangeli; F Pflumio; J T Barata
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

2.  Biochemical Feature of LMO2 Interactome and LMO2 Function Prospect.

Authors:  Wenhao Wang; Yaxin Chen; Ying Chang; Wei Sun
Journal:  Med Sci Monit Basic Res       Date:  2020-07-27

3.  The Role of TAL1 in Hematopoiesis and Leukemogenesis.

Authors:  E R Vagapova; P V Spirin; T D Lebedev; V S Prassolov
Journal:  Acta Naturae       Date:  2018 Jan-Mar       Impact factor: 1.845

4.  Ectopic FOXP3 Expression Preserves Primitive Features Of Human Hematopoietic Stem Cells While Impairing Functional T Cell Differentiation.

Authors:  F R Santoni de Sio; L Passerini; M M Valente; F Russo; L Naldini; M G Roncarolo; R Bacchetta
Journal:  Sci Rep       Date:  2017-11-17       Impact factor: 4.379

Review 5.  Notch and NF-κB: Coach and Players of Regulatory T-Cell Response in Cancer.

Authors:  Francesca Ferrandino; Paola Grazioli; Diana Bellavia; Antonio Francesco Campese; Isabella Screpanti; Maria Pia Felli
Journal:  Front Immunol       Date:  2018-10-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.